Seminal gene-modified tumor cell-based clinical trials were initiated and have continued for nearly a decade at Johns Hopkins University (JHU). These clinical studies were based upon NIH-funded Principal Investigators' discovery and development of basic research concepts, with various commercial entities manufacturing and releasing the clinical products. The Cell Processing and Gene Therapy Core (CPGT) was established in 2000 to manufacture clinical grade biotherapeutic material for Phase l/ll clinical gene therapy trials at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins. Oversight and resource utilization of the Cell Processing and Gene Therapy Core occurs under the direction of a dedicated committee. The Cell Processing and Gene Therapy Core is composed of two components: a 400 square foot Process Optimization Lab (POL) and an 1800 square foot cGMP facility comprised of 4 manufacturing suites, a general processing area, storage, gown in and gown out areas. The Process optimization lab is shared by the Cellular] Therapy Core and all three labs operate under shared management and oversight. This Core has been utilized by 15 faculty members who represent 9 programs within the SKCCC. This facility supports the entire Johns Hopkins community in the translation of research concepts to human somatic cell and gene therapy clinical trials. The mission of the Core is to: 1) produce expanded cell-therapy and gene-therapy based biotherapeutic products for Phase I and II clinical studies. Production employs current Good Manufacturing Practices (cGMP) as required by federal regulations. 2) manufacture novel biological oncolytic agents and clinical grade biotherapeutic] reagents that require cGMP, as mandated by the FDA 3) serve as a regulatory resource to the SKCCC membership in the preparation of cell and gene- therapy based INDs. To date the Cell Processing and Gene Therapy Core has manufactured 10 different types of products. This Core will continue facilitating clinical development of novel cancer therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-46
Application #
7726518
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
46
Fiscal Year
2008
Total Cost
$227,723
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Lee, Alice J; Montgomery, Madeline C; Patel, Rupa R et al. (2018) Improving Insurance and Health Care Systems to Ensure Better Access to Sexually Transmitted Disease Testing and Prevention. Sex Transm Dis 45:283-286
Bharathy, Narendra; Berlow, Noah E; Wang, Eric et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma. Sci Signal 11:
Ambinder, Richard F (2018) A viral protein kinase drug target for tumors? J Clin Invest 128:2197-2198
Huang, Peng; Park, Seyoun; Yan, Rongkai et al. (2018) Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. Radiology 286:286-295
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
McGrath-Morrow, Sharon A; Ndeh, Roland; Helmin, Kathryn A et al. (2018) DNA methylation regulates the neonatal CD4+ T-cell response to pneumonia in mice. J Biol Chem 293:11772-11783
Connolly, Roisin M; Fackler, Mary Jo; Zhang, Zhe et al. (2018) Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat 167:107-116
Ye, I Chae; Fertig, Elana J; DiGiacomo, Josh W et al. (2018) Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes. Mol Cancer Res 16:1889-1901
Kaur, Harsimar B; Guedes, Liana B; Lu, Jiayun et al. (2018) Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol 31:1539-1552
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74

Showing the most recent 10 out of 2393 publications